Delving into the Latest Updates on Cernilton with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

CN-009, Cernitin, セルニルトン

Target-

Mechanism-

Therapeutic Areas

Urogenital Diseases

Active Indication

Chronic prostatitisProstatic Hyperplasia

Inactive Indication-

Originator Organization

Tobishi Pharmaceutical Co. Ltd.

Active Organization

Tobishi Pharmaceutical Co. Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (05 Sep 1968),

Chronic prostatitisProstatic Hyperplasia

Regulation-

Login to view timeline

In this placebo controlled study the safety and efficacy of Cernilton, a standardized pollen extract, in men with inflammatory chronic prostatitis-chronic pelvic pain syndrome was investigated. The purpose of this study is to determine whether Cernilton is safe and effective in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome.

Start Date01 Dec 1999

Sponsor / Collaborator

University of Giessen

[+1]

100 Clinical Results associated with Cernilton

Login to view more data

100 Translational Medicine associated with Cernilton

Login to view more data

100 Patents (Medical) associated with Cernilton

Login to view more data

66

Literatures (Medical) associated with Cernilton

01 Feb 2021·Wiener klinische WochenschriftQ4 · MEDICINE

A glimpse into the efficacy of alternative therapies in the management of benign prostatic hyperplasia

Q4 · MEDICINE

Review

Author: Hossain, Md Amir ; Zhou, Xiaohui ; Wazir, Junaid ; Ihsan, Awais Ullah ; Ullah, Rahat ; Khan, Farhan Ullah ; Diallo, Maladho Tanta

Benign prostatic hyperplasia (BPH) is a common disease that can cause uncomfortable lower urinary tract symptoms. The occurrence of symptomatic BPH develops after the age of 40 years and increases gradually with age to reach more than 50% at the age of 60 years and severely disturbs the quality of life of the patients. Alpha-blockers and 5‑alpha reductase inhibitors are first-line agents used for the treatment of BPH. Due to the adverse effects of these conventional therapies, many patients turn to phytotherapy and other alternative therapies. This review covers alternative therapies, i.e., phytotherapy (cernilton, eviprostat, quercetin, saw palmetto and pumpkin seed) and physical therapy (acupuncture, aquablation, pulsed electromagnetic field, prostate urethral lift, radial extracorporeal shock wave therapy, thermobalancing therapy, and transurethral needle ablation) commonly used in the management of BPH.

01 Sep 2020·Neurourology and urodynamicsQ3 · MEDICINE

Comparison of cernitin pollen extract vs tadalafil therapy for refractory chronic prostatitis/chronic pelvic pain syndrome: A randomized, prospective study

Q3 · MEDICINE

Article

Author: Fujita, Takashi ; Ishida, Shohei ; Funahashi, Yasuhito ; Naito, Yushi ; Gotoh, Momokazu ; Tochigi, Kosuke ; Matsukawa, Yoshihisa ; Kato, Masashi

Abstract:

Aims:

To compare the efficacy of cernitin pollen extract (cernitin) or tadalafil for treating persistent chronic pelvic pain despite α1‐blocker monotherapy in men with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and lower urinary tract symptoms (LUTS).

Methods:

A total of 100 patients with refractory CP/CPPS despite ongoing α1‐blocker monotherapy were randomized to receive add‐on therapy with either cernitin (4 capsules/day) or tadalafil (5 mg/d) for 12 weeks. At week 12, changes from baseline in the patients’ CP/CPPS, LUTS, and voiding function, as assessed using the National Institutes of Health Chronic Prostatitis Symptom Index (NIH‐CPSI), the International Prostate Symptom Score (IPSS), and uroflowmetry, respectively, were compared between the groups.

Results:

The final analysis included 42 and 45 patients in the cernitin and tadalafil groups, respectively. Although the NIH‐CPSI total, NIH‐CPSI pain sub‐score, and NIH‐CPSI quality of life sub‐score significantly improved in both groups, the cernitin (vs tadalafil) group showed significantly greater improvements in the NIH‐CPSI total score (−6.8 vs −4.6; P = .02) and NIH‐CPSI pain sub‐score (−4.1 vs −1.5; P < .001). Half (50%) of the patients in the cernitin group showed a reduction greater than 50% in their NIH‐CPSI pain sub‐score; in the tadalafil group, only four patients (8.9%) showed ≥50% improvement (P < .001). In contrast, the improvement in LUTS was significantly superior in the tadalafil group.

Conclusion:

Both cernitin and tadalafil significantly ameliorated chronic pelvic pain in patients with refractory CP/CPPS. The add‐on of cernitin was more effective than tadalafil for pelvic pain and discomfort.

01 Jan 2020·Pharmaceutical biologyQ3 · MEDICINE

The effect of Jiedu Huoxue decoction on rat model of experimental nonbacterial prostatitis via regulation of miRNAs

Q3 · MEDICINE

ArticleOA

Author: Wang, Jiangang ; Mao, Wenli ; Yi, Jun ; Yan, Zhangren ; Huang, Chunhua ; Wang, Wanchun ; Huang, Gang ; Wu, Yunbo

CONTEXT:

The underlying mechanisms of Jiedu Huoxue decoction (JDHXD) in treating chronic prostatitis have not been fully explored.

OBJECTIVE:

This study investigates the miRNAs as potential biomarkers and the effect of JDHXD on the rat model of experimental nonbacterial prostatitis.

MATERIALS AND METHODS:

Fifty-four Sprague-Dawley male rats were randomly divided into normal control, model, JDHXD low dose (0.5 g/kg/day), medium dose (1 g/kg/day), high dose (2 g/kg/day) and western medicine (cernilton 0.094 g/kg/day) groups, and intragastrically administered once daily for 30 days. The control and model (upon successful establishment) groups received distilled water. Differential expression of miRNAs was analysed with high-throughput miRNA sequencing and validated with qRT-PCR and Northern blot. Prediction of specific target genes and functional enrichment analysis were performed with bioinformatics.

RESULTS:

LD₅₀ test showed no sign of toxicity with maximum feasible dose 4 g/kg JDHXD. Compared with control, 495 miRNAs showed expression changes in CAP/CPPS rats, of which 211 were significantly different and 37 were prostatic-related. There were 181 differentially expressed miRNAs between the model and high dose JDHXD groups, of which 23 were identical with the control and model groups. Compared with control, miR-146a, miR-423 and miR-205 expression increased significantly in the model group, decreased dose-dependently in the JDHXD groups (p < 0.05), and vice-versa for miR-96 (p < 0.05). The effect of low dose JDHXD was comparable to cernilton (p > 0.05).

DISCUSSION AND CONCLUSIONS:

Future studies may explore the contributions of the active components in JDHXD. The study design is generalisable. The effect can be repeatedly verified in clinical trials.

100 Deals associated with Cernilton

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	G04C	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Chronic prostatitis	JP	Tobishi Pharmaceutical Co. Ltd.	05 Sep 1968
Prostatic Hyperplasia	JP	Tobishi Pharmaceutical Co. Ltd.	05 Sep 1968

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00919893 (CTgov)	Phase 3	Chronic pelvic pain syndrome \| Chronic prostatitis	139	Cernilton (Cernilton)	rpmeedvvjq(zuoatepacg) = tcnxkoktiq guphubhxzg (qxyyrttrjv, putrkphuzl - flbqgwwbso) View more	-	12 Jun 2009
				Placebo (Placebo)	rpmeedvvjq(zuoatepacg) = quhgvruhax guphubhxzg (qxyyrttrjv, vrhskojwyw - uetvfsprii) View more